Previous close | 6.86 |
Open | 6.91 |
Bid | 6.70 x N/A |
Ask | 6.97 x N/A |
Day's range | 6.58 - 6.91 |
52-week range | 3.66 - 9.81 |
Volume | |
Avg. volume | 5 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?